Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453711 · ClinicalTrials.gov registry record · Phase 2
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 957
- Enrollment target
NCT02453711: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT02453711 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 957 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (620% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02453711, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 957 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Primary Outcome
Relative change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site
Interventions
- DRUG placebo
- DRUG semaglutide
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 957 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2017-04-12 |
| Phase | Phase 2 |
What the finished NCT02453711 record still lists
NCT02453711 is an interventional study that assigns participants to a tested intervention. The registered 957 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (620% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02453711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02453711 about?
NCT02453711 is a clinical study titled "Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus". This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
What is the current status of trial NCT02453711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 957 participants. The study started on 2015-10-01. Estimated completion is 2017-04-12.
What interventions are being tested in trial NCT02453711?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT02453711?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02453711's enrollment target sits among peer trials
957 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI